Modality
ADC
MOA
BTKi
Target
GPRC5D
Pathway
T-cell
Gastric CaHNSCCGBM
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Apr 2027
Phase 2Current
NCT03713446
785 pts·HNSCC
2024-08→2026-03·Terminated
NCT07862371
1,705 pts·Gastric Ca
2023-02→2027-04·Active
2,490 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-182w agoPh3 Readout· HNSCC
2027-04-101.0y awayPh3 Readout· Gastric Ca
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2026-03-18 · 2w ago
HNSCC
Ph3 Readout
2027-04-10 · 1.0y away
Gastric Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03713446 | Phase 2/3 | HNSCC | Terminated | 785 | HAM-D |
| NCT07862371 | Phase 2/3 | Gastric Ca | Active | 1705 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 |